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(Eingegangen am 3. Oktober 1967)
A method has been described for the determination of individual Unconjugated 17-oxosteroids in human urine. The procedure involves the
immediate extraction of the sample, purification steps and a paper Chromatographie separation of steroids. The 17-oxosteroids were
evaluated by a Zimmermann-reaction in situ on the paper, elution of chromogens and spectrophotometry. Values for the excretion of
Unconjugated metabolites by healthy female subjects under basal conditions, following corticotrophin and metopirone stimulation, and
after administration of testosterone-propionate were also presented. Only very low levels and a preponderance of the 5/?-reduced meta-
bolites were observed in the urines studied.
Es wird eine Methode f r die Bestimmung der einzelnen unkonjugierten 17-Oxosteroide in Menschenharn beschrieben. Das Verfahren
besteht in der direkten Extraktion der Probe, Reinigungsschritten und einer papierchromatographischen Trennung der Steroide. Die
17-Oxosteroide werden bestimmt durch eine Zimmermann-Reaktion in situ auf dem Papier, Elution der Farbstoffe und Spektrophoto-
metrie. Werte f r die Ausscheidung unkonjugierter Metabolite bei gesunden weiblichen Probanden unter Normalbedingungen, nach
ACTH- und Metopiron-Stimulation und nach Applikation von Testosteronpropionat werden ebenfalls angegeben. Nur sehr geringe
Mengen und ein berweigen der 5 -reduzierten Metabolite werden in den untersuchten Harnen beobachtet.
Earlier observations on the androgen metabolites of
human urine refer to the total amounts of individual
17-oxosteroids, representing the sum of the free and
esterified metabolites (1). Some recent methods are
related to the fractionation of glucuronides and
sulphates (2, 3). Only fragmentary data are available on
the excretion of individual Unconjugated 17-oxo-
steroids by humans (4—7).
The occurrence of free etiocholanolone1) in the plasma
of subjects with "etiocholanolone-fever" has been
reported in the literature (8—10). These publications
contain merely references and no firm data on the
patterns of Unconjugated 17-oxosteroids in the urine
of patients with the syndrome.
In the course of our study on cases of etiocholanolone-
fever the 17-oxosteroids were determined simultaneously
in plasma and urine (11). In the present communication
the procedure and the normal values for individual
free 17-oxosteroids in urine measured under basal
conditions and following administration of cortico-
trophin (ACTH), metopirone or testosterone-propionate
are described.
Method
The procedure for the determination of Unconjugated steroids in
urine utilizes the main steps involved in a previous technique for
measuring the amount of individual 17-oxosteroids following
hydrolysis, i. e. those excreted mainly as conjugates (12). In order
to avoid the spontaneous hydrolysis of conjugates, the deter-
minations were made immediately after the collection of urine.
A 200 m/ aliquot of 24 h urine was extracted three times with
100 m/ of peroxide-free ether. Emulsions were broken by adding
a few m/ of etihanol. The combined extracts were washed with-
40 m/ of N NaOH and 40 m/ of water, dried over anhydrous
Na2SQ4 and evaporated. The residue was dissolved in absolute
ethanol, then aliquots equivalent to 50 to 100 m/ urine, together
with reference standards, were applied to Whatman No 1 paper.
x) Synonyms in the publication: HOE: 3α, ll/?-dilhydroxy-5/?-andro-
stan-17-one, 11-OH-etiocholanolone. HO Α: 3α, lljff-dihydroxy-
5a-androstan-17-one, 11-OH-amdrosterone. OE: 3a-hydroxy-
5jff-androstan-ll, 17-dione, 11-keto-etiocholanolone. DEA: 3^3-
hydroxy-androst-5-en-17-one, dehydroepiandrosterone. Ε: 3α-
hydroxy-5£-androstai>17-one, etiocholanolone. A: Sa^hydroxy-
5a-androstan-17-one, androsterone. Testosterone: 17^-hydfoxy-
androst-4^en-3-one.
The paper was then impregnated with 30% propylene glycol in
methanol, and the steroids were chromatographed in the solvent
system, ligroin (b. p. 100—130°)/benzene/methanol (130:60:10 v/v).
For the quantitative determination, Zimmermann-reaction was
carried out in situ, the steroid chromogens were eluted and meas-
ured spectrophotometrically (12). The values were expressed in
androsterone equivalents.
The general basis of the method has been eperimentally verified
and the results were described previously (12). Furthermore, to
check that no spontaneous hydrolysis of steroid conjugates
occurred, 200/ig dehydroepiandrosterone-sulphate were added
to 200 m/ specimens of urine, and then processed as described
above. No free DEA was observed by subsequent chromato-
graphy and Zimmermann-reaction. According to the experiments,
the sensitivity of the method was 3^g/24h determined by the
lowest quantitative limit of evaluation and by the volume of
urine processed. Recovery of DEA, Ε and A added in 3 to 30 μ%
amounts to 200 m/aliquots of urine in six experiments was 86 ± 4%
(mean ± S. E.). The structure of the steroids was supported by
paper chromatography and thin-layer chromatography on silica
gel G, by various colour reactions and by the formation of deri-
vatives (12—14).
Normal individuals in the present study included females between
16 and 38 years of age. These subjects were members of the staff
or patients exhibiting no endocrine abnormalities. The menstrual
cycle was disregarded during the experiments.
Excretion of Unconjugated 17-oxosteroids was determined,
1. under basal conditions,
2. following stimulation of adrenals by two subsequent injections
of 80 U ACTH (Exacthin, RICHTER, Budapest) i. m. and
3. during oral administration of 6 X 0.5 g metopirone (CiBA,
Basel) for two days (15). Furthermore,
4. testosterone-propionate (Androfort, RICHTER, Budapest) was
administered in 30 mg/day dose levels i. m. for 5 consecutive
days and the urine collected on the last day of therapy (16).
Results
The amounts of individual free 17-oxosteroids in the
urine of female subjects under basal conditions and
after the administration of ACTH, metopirone or
testosterone-propionate are shown in Table 1. For
comparison, the mean values of conjugates (including
free steroids) calculated from data reported in detail
previously (17) are also indicated.
According to the present investigation, the excretion
of individual Unconjugated 17-oxosteroids varied from
undetectable amounts to 44^g/24h, the highest indivi-
dual value under physiological conditions. There was a
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predominance of 5/?-steroids in the urine of the female
subjects studied (mean 5/S/5a ratio 6.0). Following
administration of ACTH, metopirone or testosterone
the urinary output of free steroids increased, as has
been routinely observed for conjugates (1, 16). It is
noteworthy that injection of testosterone-propionate
enhanced the excretion of HOE or OE and that prac-
tically no HOA was isolated from urines irrespective of
the condition of measurement. As shown further in
Table 1, the 5/?/5a ratio of unconjugated metabolites
generally increased after ACTH and metopirone
stimulation or following testosterone.
As regards unconjugated E, the steroid was present in
almost every urine sample (mean basal 10/jg/24h) and
its amount did not exceed 79 /*g/24h after any treatment.
Tab. 1.
Excretion of individual unconjugated 17-oxosteroids by normal
female subjects under physiological conditions and after the ad-























































































































*> Not detectable by the method employed.









































































To our knowledge, only fragmentary data are available
on the excretion of unconjugated 17-oxosteroids in
human urine. These refer only to one or other of
steroid metabolites (A—6), or to the C19O3 and C19O2
fractions without any separation of individual com-
ponents (7).
In the present study, the individual free 17-oxosteroids
were determined in the urine of normal female subjects
linder various conditions. Only minute amounts of the
steroids could be detected.
It is known that the 3a(OH)-steroids are conjugated
chiefly as their glucuronides, and the 3ß(OH)-steroids
as their sulphate conjugates in urine (1—5). Thus it
can be concluded that the mode of conjugation is
determined by the structure of the molecule. Con-
jugated HOE, HOA and OE are the main 11-oxygenated
17-oxosteroids in urine (1) and, according to the present
study, no HOA but significant amounts of HOE and
OE are detectable in the free fraction. These obser-
vations support the hypothesis that not only the mode
but the effectivity of conjugation is determined by the
constitution of steroid metabolite.
Although largely identical amounts of 5ß- and 5 -
reduced 17-oxosteroids are excreted as conjugates
(1, 2, 17), a preponderance of the free 5/?-steroids in the
urine of female subjects was observed here under
physiological conditions. Furthermore, the 5ß/5oc ratio
of unconjugated steroids increased when the endo-
genous production of precursors was stimulated by
ACTH and metopirone, or following the administration
of exogenous testosterone,.which is one of the common
precursors of ll-deoxy-17-oxosteroids.
From the findings it may be concluded that the androgen
metabolism in female subjects is characterised by a
reduced activity of 5/?-conjugation and/or a certain
renal selectivity towards the appearance of unconju-
gated 5j8-steroids in urine.
We wish to thank Prof. K. JUNKMANN, Schering AG Berlin, for the
courtesy of a gift of dehydroepiendrosterone sulphate.
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